• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

GSK2239633A

CAS No. 1240516-71-5

GSK2239633A ( —— )

产品货号. M26236 CAS No. 1240516-71-5

GSK2239633A 是 CC 趋化因子受体 4 (CCR4) 的变构拮抗剂,[125I]-TARC 与人 CCR4 结合的 pIC50 为 7.96。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥1037 有现货
10MG ¥1725 有现货
25MG ¥3686 有现货
50MG ¥5443 有现货
100MG ¥7744 有现货
500MG ¥15552 有现货
1G 获取报价 有现货

生物学信息

  • 产品名称
    GSK2239633A
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    GSK2239633A 是 CC 趋化因子受体 4 (CCR4) 的变构拮抗剂,[125I]-TARC 与人 CCR4 结合的 pIC50 为 7.96。
  • 产品描述
    GSK2239633A is an allosteric antagonist of CC-chemokine receptor 4 (CCR4) with a pIC50 of 7.96 for the binding of [125I]-TARC to human CCR4.(In Vitro):GSK2239633A increases the CCL17-induced F-actin content of human CD4+ CCR4+ T cells with a pEC50 value of 8.79±0.22. GSK2239633A inhibits thymus- and activation-regulated chemokine-induced (TARC)-induced increases in the F-actin content of isolated human CD4+ CCR4+ T-cells with a pA2 of 7.11±0.29.(In Vivo):GSK2239633A demonstrates good pharmacokinetic data in preclinical animal studies with bioavailability in rats and beagle dogs of 85% and 97% respectively. Plasma GSK2239633A (i.v.) displays rapid, bi-phasic distribution and slow terminal elimination (13.5 h), suggesting that GSK2239633A is a low to moderate clearance drug. Blood levels of GSK2239633A(oral) reach Cmax rapidly (median tmax: 1.0-1.5 hours).
  • 体外实验
    The GSK2239633A is an allosteric antagonist of human CCR4.GSK2239633A inhibits the binding of [125I]-TARC to human CCR4 with a pIC50 of 7.96±0.11 and also inhibits thymus- and activation-regulated chemokine-induced (TARC)-induced increases in the F-actin content of isolated human CD4+ CCR4+ T-cells with a pA2 of 7.11±0.29. The effect of GSK2239633A(Compound 3) on CCL17-induced increases in the F-actin content of human CD4+ CCR4+ T cells is measured. The pEC50 value is 8.79±0.22.
  • 体内实验
    Following intravenous dosing, plasma GSK2239633A displays rapid, bi-phasic distribution and slow terminal elimination (t1/2: 13.5 hours), suggesting that GSK2239633A is a low to moderate clearance drug. Following oral dosing, blood levels of GSK2239633A reach Cmax rapidly (median tmax: 1.0-1.5 hours). Estimated GSK2239633A bioavailability is low with a maximum value determined of only 16%. GSK2239633A (Compound 9) demonstrates good pharmacokinetic data in preclinical animal studies (bioavailability in rats and beagle dogs 85% and 97% respectively).
  • 同义词
    ——
  • 通路
    Autophagy
  • 靶点
    CCR
  • 受体
    Dopamine| Norepinephrine| serotonin
  • 研究领域
    ——
  • 适应症
    ——

化学信息

  • CAS Number
    1240516-71-5
  • 分子量
    549.06
  • 分子式
    C24H25ClN4O5S2
  • 纯度
    >98% (HPLC)
  • 溶解度
    In Vitro:?DMSO : ≥ 250 mg/mL (455.32 mM)
  • SMILES
    COc1cccc2n(Cc3cccc(CNC(=O)C(C)(C)O)c3)nc(NS(=O)(=O)c3ccc(Cl)s3)c12
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1.Li R, Sahu S, Schachner M. Phenelzine, a cell adhesion molecule L1 mimetic small organic compound, promotes functional recovery and axonal regrowth in spinal cord-injured zebrafish. Pharmacol Biochem Behav. 2018 Aug;171:30-38.
产品手册
关联产品
  • GSK2239633A

    GSK2239633A 是 CC 趋化因子受体 4 (CCR4) 的变构拮抗剂,[125I]-TARC 与人 CCR4 结合的 pIC50 为 7.96。

  • Cenicriviroc

    Cenicriviroc 是一种口服活性的 CCR2/CCR5 双重拮抗剂。它还可以抑制 HIV-1 和 HIV-2,并具有有效的抗感染和抗炎活性。

  • INCB 3284

    INCB 3284 是一种有效的,选择性的人 CCR2 拮抗剂,能够抑制单核细胞趋化蛋白 1 与 hCCR2 结合,IC50 值为 3.7 nM。INCB 3284 可用于急性肝功能衰竭的研究。